跳至主要内容
临床试验/EUCTR2009-011088-35-DE
EUCTR2009-011088-35-DE进行中(未招募)1 期

Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial - PACAMUS

Philipps-Universität Marburg0 个研究点目标入组 2 人开始时间: 2010年2月5日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
2

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - informed consent
  • - age: 18 to 60 years
  • - diagnosis CIS or relapsing remitting MS
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - patient younger than 18 or older than 60 years old
  • - primary or secondary progressive MS
  • - other autoimmune disease
  • - pregnancy
  • - ineffective contraception
  • - other immunosuppressive or immunomodulatory treatment except corticosteroids in case of a relapse
  • - intolerance to glatiramer acetate or mannitol
  • - contraindication against glatiramer acetate
  • - infectious disease or surgery within four months before study inclusion
  • - renal insufficiency
  • - cancer in the medical history
  • - severe heart disease in the medical history
  • - participation in another study

研究者

相似试验